In a report released on January 3, Brian Abrahams from RBC Capital maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $27.00. The company’s shares closed yesterday at $27.90.
According to TipRanks, Abrahams is a 5-star analyst with an average return of 7.6% and a 49.80% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Biogen, Sarepta Therapeutics, and BioCryst.
PTC Therapeutics has an analyst consensus of Hold, with a price target consensus of $27.18.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $59.84 and a one-year low of $17.53. Currently, PTC Therapeutics has an average volume of 1.35M.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PTCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics (PTCT) Company Description:
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Read More on PTCT:
- Amgen upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
- PTC Therapeutics downgraded to Underweight at Morgan Stanley
- PTC Therapeutics initiated with an Overweight at Wells Fargo
- PTC Therapeutics initiated with bullish view at Wells Fargo
- PTC Therapeutics provides regulatory update for Translarna in Europe, the U.S.
